Recursion Pharmaceuticals (RXRX) Q2 FY26 earnings call

Recursion Pharmaceuticals reported a strong quarter, highlighting the maturation of its AI-native product engine into a system capable of generating differentiated programs and medicines. The company demonstrated significant progress across its internal clinical pipeline and external partnerships, notably advancing a novel neuroscience target with Roche-Genentech. Management also emphasized substantial operational efficiencies, leading to a significant reduction in full-year operating expense guidance, while maintaining a focus on high-value asset development.